Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MEDICAL DEVICE ELECTROMAGNETIC INTERFERENCE HEARING SCHEDULED BY REP. CONDIT

This article was originally published in The Gray Sheet

Executive Summary

MEDICAL DEVICE ELECTROMAGNETIC INTERFERENCE HEARING SCHEDULED BY REP. CONDIT for the first week in October, if Congress is still in session. Rep. Gary Condit's (D-Calif.) House Government Operations/Justice, Transportation, and Agriculture Subcommittee plans to address concerns at the hearing related to electromagnetic interference with medical devices caused by wireless communications products such as cellular phones. Vulnerable medical devices to be discussed at the hearing include power wheelchairs, blood gas monitors, hearing aids, pacemakers, and apnea monitors, according to staffers.

You may also be interested in...



WHO Refines Approach For Listing Products In Health Emergencies

A revised procedure is in place to temporarily list unlicensed products for use in public health emergencies. 

Pfizer Will Not Launch EU Adalimumab

Pfizer has announced that it does not plan to market its Amsparity adalimumab biosimilar in Europe despite it having been endorsed by the EMA in December and being in line for an imminent approval from the European Commission.

New Arthroscopy Tubing Guidance Aims To Reduce Cross-Contamination

Developers of arthroscopy tubing should take additional steps to reduce the risk of patient cross-contamination, the US FDA recommends in a new draft guidance document.

UsernamePublicRestriction

Register

MT002860

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel